Health Care & Life Sciences » Biotechnology | Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
9,334.00
11,933.00
77,609.00
144,011.00
128,863
Total Accounts Receivable
523.00
715.00
2,241.00
3,221.00
6,511
Other Current Assets
56.00
1,558.00
3,394.00
3,715.00
2,129
Total Current Assets
9,913.00
14,206.00
83,244.00
150,947.00
137,503
Net Property, Plant & Equipment
415.00
609.00
562.00
879.00
861
Total Investments and Advances
-
30.00
10,180.00
11,908.00
450
Other Assets
-
-
4.00
-
-
Total Assets
10,328.00
14,845.00
93,990.00
163,734.00
139,472
Accounts Payable
349.00
1,247.00
-
1,257.00
Other Current Liabilities
1,001.00
1,879.00
6,435.00
41,298.00
Total Current Liabilities
1,350.00
3,126.00
6,435.00
42,555.00
Other Liabilities
1,023.00
2,123.00
-
547.00
Total Liabilities
2,373.00
5,249.00
6,435.00
43,102.00
Common Equity (Total)
12,621.00
27,400.00
87,555.00
120,632.00
Total Shareholders' Equity
7,955.00
9,596.00
87,555.00
120,632.00
Total Equity
7,955.00
9,596.00
87,555.00
120,632.00
Liabilities & Shareholders' Equity
10,328.00
14,845.00
93,990.00
163,734.00
Preferred Stock (Carrying Value)
20,576.00
36,996.00
-
-

About Protagonist Therapeutics

View Profile
Address
7707 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.protagonist-inc.com
Updated 07/08/2019
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It offers proprietary peptide technology platform, which discovers and develops new chemical entities to address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively.